2. Academic Validation
  3. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

  • Cancer Discov. 2024 Jan 12;14(1):76-89. doi: 10.1158/2159-8290.CD-23-0964.
William K Kelly # 1 2,  Daniel C Danila # 3 4,  Chia-Chi Lin 5,  Jae-Lyun Lee 6,  Nobuaki Matsubara 7,  Patrick J Ward 2 8,  Andrew J Armstrong 9,  David Pook 10,  Miso Kim 11,  Tanya B Dorff 12,  Stefanie Fischer 13,  Yung-Chang Lin 14,  Lisa G Horvath 15,  Christopher Sumey 16,  Zhao Yang 17,  Gabor Jurida 17,  Kristen M Smith 18,  Jamie N Connarn 18,  Hweixian L Penny 17,  Julia Stieglmaier 19,  Leonard J Appleman 20
Affiliations

Affiliations

  • 1 Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania.
  • 2 Sarah Cannon Research Institute, Nashville, Tennessee.
  • 3 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • 4 Department of Medicine, Weill Cornell Medical College, New York, New York.
  • 5 National Taiwan University Hospital, Taipei, Taiwan.
  • 6 Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • 7 National Cancer Center Hospital East, Chiba, Japan.
  • 8 Oncology Hematology Care, Cincinnati, Ohio.
  • 9 Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, North Carolina.
  • 10 Monash Health, Clayton, Victoria, Australia.
  • 11 Seoul National University Hospital, Seoul, South Korea.
  • 12 City of Hope, Duarte, California.
  • 13 Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
  • 14 Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • 15 Chris O'Brien Lifehouse, University of Sydney, Sydney, New South Wales, Australia.
  • 16 Sanford Cancer Center, Sioux Falls, South Dakota.
  • 17 Amgen Inc., Thousand Oaks, California.
  • 18 Amgen Inc., South San Francisco, California.
  • 19 Amgen Research (Munich) GmbH, Munich, Germany.
  • 20 UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • # Contributed equally.
PMID: 37861461 DOI: 10.1158/2159-8290.CD-23-0964
Abstract

Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)-targeted T-cell engager designed to facilitate lysis of STEAP1-expressing Cancer cells, such as those in advanced prostate Cancer. This first-in-human study reports monotherapy dose exploration for patients with metastatic castration-resistant prostate Cancer (mCRPC), primarily taxane pretreated. Ninety-seven patients received ≥1 intravenous dose ranging from 0.001 to 2.0 mg weekly or every 2 weeks. MTD was identified as 1.5 mg i.v. weekly via a 3-step dose. The most common treatment-related adverse events were cytokine release syndrome (CRS; 72%), fatigue (45%), and myalgia (34%). CRS occurred primarily during cycle 1 and improved with premedication and step dosing. Prostate-specific antigen (PSA) and RECIST responses across cohorts were encouraging [49% PSA50; 24% objective response rate (ORR)], with greater frequency at target doses ≥0.75 mg (59% PSA50; 41% ORR). Xaluritamig is a novel immunotherapy for prostate Cancer that has shown encouraging results supporting further development.

Significance: Xaluritamig demonstrated encouraging responses (PSA and RECIST) compared with historical established treatments for patients with late-line mCRPC. This study provides proof of concept for T-cell engagers as a potential treatment for prostate Cancer, validates STEAP1 as a target, and supports further clinical investigation of xaluritamig in prostate Cancer. See related commentary by Hage Chehade et al., p. 20. See related article by Nolan-Stevaux et al., p. 90. This article is featured in Selected Articles from This Issue, p. 5.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z